There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC) and Aeglea Biotherapeutics (AGLE) with bullish sentiments.
Atricure (ATRC)
BTIG analyst Marie Thibault reiterated a Buy rating on Atricure yesterday and set a price target of $56.00. The company’s shares closed last Thursday at $37.12.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 30.0% and a 56.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Irhythm Technologies.
Atricure has an analyst consensus of Moderate Buy, with a price target consensus of $56.00.
See today’s analyst top recommended stocks >>
Aeglea Biotherapeutics (AGLE)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Aeglea Biotherapeutics yesterday and set a price target of $16.00. The company’s shares closed last Thursday at $8.56.
According to TipRanks.com, Slutsky is a 4-star analyst with an average return of 22.0% and a 54.3% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, BELLUS Health, and Allakos.
Aeglea Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $16.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
